PHARMADEVILS

QULITY ASSURANCE DEPARTMENT

HOLD TIME STUDY PROTOCOL CUM REPORT FOR ORAL LIQUID

HOLD TIME STUDY PROTOCOL

FOR
ORAL LIQUID

PROTOCOL NO.

SUPERCEDES Nil

PROTOCOL EFFECTIVE DATE

REPORT EFFECTIVE DATE

 PHARMADEVILS
QULITY ASSURANCE DEPARTMENT

HOLD TIME STUDY PROTOCOL CUM REPORT FOR ORAL LIQUID

CONTENTS

0.0 PROTOCOL PREAPPROVAL..........................................................................3

1.0 OBJECTIVE.................................................................................................4

2.0 INTRODUCTION..........................................................................................4

3.0 RESPONSIBILITIES....................................................................................4

4.0 PROCEDURE...............................................................................................5

5.0 MATRIX & SPECIFICATION FOR HOLD TIME STUDY................................6-9

6.0 DEVIATION AND CHANGE CONTROL.........................................................10

7.0 SUMMARY AND CONCLUSION...................................................................10

8.0 REFERENCE……………………………………………………………………………………..10

9.0 ABBREVIATION……………………………………………………………………………….10

10.0 POST APPROVAL....................................................................................11

 PHARMADEVILS
QULITY ASSURANCE DEPARTMENT

HOLD TIME STUDY PROTOCOL CUM REPORT FOR ORAL LIQUID

1.0 PROTOCOL PREAPPROVAL

PROTOCOL PREPARED BY:

DEPARTMENT NAME DESIGNATION SIGNATURE DATE

QUALITY ASSURANCE

PROTOCOL REVIEWED BY:

DEPARTMENT NAME DESIGNATION SIGNATURE DATE

PRODUCTION

QUALITY CONTROL

PROTOCOL APPROVED BY:

DEPARTMENT NAME DESIGNATION SIGNATURE DATE

QUALITY ASSURANCE
 PHARMADEVILS
QULITY ASSURANCE DEPARTMENT

HOLD TIME STUDY PROTOCOL CUM REPORT FOR ORAL LIQUID

1.0 Objective:
The objective of this protocol is to study the effect of “Hold Time” on the bulk of
…………………………………………………………………….. to verify that during the hold
period, the Product shall meet predetermined quality specifications. The protocol also details the
responsibilities and activities associated with this Hold Time Study.

2.0 Introduction:
The Samples of ………………………………………………………………… subjected to Hold
Time Study shall be stored under simulated conditions and shall be analyzed as per the established
specifications at different time points of study as specified.
Analytical methods for testing of bulk of …………………………………. have been satisfactorily
adopted into the QC laboratory.
On completion of the study, a report shall be prepared and final conclusion shall be drawn in the
same. It shall be implemented in routine manufacturing. This document shall form the basis of the
production scale batches. Any variation to the established Hold Time shall be explained and justified,
in accordance with the change control procedure.

3.0 RESPONSIBILITIES:
S.No Department Responsibilities
01 Production Review of Hold time study protocol and Report
02 Quality Control Review of Hold time study protocol & report
Analysis of samples and reporting the results
03 Quality Assurance Preparation, Review & Approval of Hold time study protocol
& report, Sampling and compilation of results

4.0 PROCEDURE:
4.1 Bulk hold time study:
Test the sample from the bulk from the three batches at Zero (0) time point. Store sample from three
batches for a period of specific time period given different process stage under simulated conditions at
Temp. NMT 27°C and Relative humidity NMT 50 %.
S.No Name of stage Sample Qty. Required for Hold time study
01 Un-Filtered Solution 2.00 ltr
02 Filtered Solution 2.00 ltr

Section 5.0 (Matrix for Hold Time Study).

Acceptance criteria:
Bulk sampled at different time points shall meet the acceptance criteria as mentioned in Table No. 1.
 PHARMADEVILS
QULITY ASSURANCE DEPARTMENT

HOLD TIME STUDY PROTOCOL CUM REPORT FOR ORAL LIQUID

5.0 Matrix for hold time study

5.1.1 Matrix for hold time study of Un-Filtered solution

Storage Time Sample Quantity for testing Tests to be performed

Type of Sample: Un-Filtered solution

300 ml Description, pH Value, wt. per ml & Assay,

Initial
(Chemical + microbiological sample) Micro

300 ml Description, pH Value, wt. per ml & Assay,

01 Day
(Chemical + microbiological sample) Micro

300 ml Description, pH Value, wt. per ml & Assay,

02 Days
(Chemical + microbiological sample) Micro

300 ml Description, pH Value, wt. per ml & Assay,

05 Days
(Chemical + microbiological sample) Micro

300 ml Description, pH Value, wt. per ml & Assay,

07 Days
(Chemical + microbiological sample) Micro

5.1.2 : specifications for Un-Filtered solution

S.No. Tests Limits

01 Description

02 pH value

03 Wt. per ml

04 Assay

Additional Test

Microbial limit test

A. Total viable aerobic count

Aerobic bacteria NMT 102 cfu/gm

05
Fungi NMT 101 cfu/gm

B. Pathogens

1. E. coli Absent
 PHARMADEVILS
QULITY ASSURANCE DEPARTMENT

HOLD TIME STUDY PROTOCOL CUM REPORT FOR ORAL LIQUID

5.2.1 Matrix for hold time study of Filtered solution

Storage Time Sample Quantity for testing Tests to be performed

Type of Sample: Filtered solution

300 ml Description, pH Value, wt. per ml & Assay,

Initial
(Chemical + microbiological sample) Micro

300 ml Description, pH Value, wt. per ml & Assay,

01 Day
(Chemical + microbiological sample) Micro

300 ml Description, pH Value, wt. per ml & Assay,

02 Days
(Chemical + microbiological sample) Micro

300 ml Description, pH Value, wt. per ml & Assay,

05 Days
(Chemical + microbiological sample) Micro

300 ml Description, pH Value, wt. per ml & Assay,

07 Days
(Chemical + microbiological sample) Micro

5.2.2 : specifications for Filtered Solution

S.No. Tests Limits

01 Description

02 pH value

03 Wt. per ml

04 Assay

Additional Test

Microbial limit test

A. Total viable aerobic count

Aerobic bacteria NMT 102 cfu/gm

05
Fungi NMT 101 cfu/gm

B. Pathogens

1. E. coli Absent
 PHARMADEVILS
QULITY ASSURANCE DEPARTMENT

HOLD TIME STUDY PROTOCOL CUM REPORT FOR ORAL LIQUID

6.0 DEVIATION AND CHANGE CONTROL:

…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
……………………………………………

7.0 SUMMARY AND CONCLUSION:

…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
…………………………………………………………………………………………………………………
……………………………………………

8.0 REFERENCE:.
ICH, FDA, EMEA and Annexure IV WHO TRS 992

9.0 ABBREVIATION:.
S.No Abbreviation Extended Form
01 SOP Standard Operating Procedure
02 HTSP HOLD Time Study Protocol
03 LOD Loss on Drying
 PHARMADEVILS
QULITY ASSURANCE DEPARTMENT

HOLD TIME STUDY PROTOCOL CUM REPORT FOR ORAL LIQUID

10.0 REPORT POSTAPPROVAL:

COMPILED BY:

DEPARTMENT NAME DESIGNATION SIGNATURE DATE

QUALITY ASSURANCE

REVIEWED BY:

DEPARTMENT NAME DESIGNATION SIGNATURE DATE

PRODUCTION

QUALITY CONTROL

APPROVED BY:

DEPARTMENT NAME DESIGNATION SIGNATURE DATE

QUALITY ASSURANCE
 PHARMADEVILS
QULITY ASSURANCE DEPARTMENT

HOLD TIME STUDY PROTOCOL CUM REPORT FOR ORAL LIQUID

Annexure I

RESULTS OF UN-FILTERED SOLUTION

BATCH NO. MFG. DATE

BATCH SIZE EXP. DATE

01 Days

02 Days

05 Days

07 Days
(Initial)
0 hours
Sr. No. Tests Limits

01 Description

02 pH Value

03 Wt.per ml

04 Assay

Additional Test

Microbial limit test

A. Total viable aerobic count

Aerobic NMT 102

bacteria cfu/g
05
NMT 101
Fungi
cfu/g

B. Pathogens

1. E. coli Absent

Compiled By________________ Reviewed By______________

 PHARMADEVILS
QULITY ASSURANCE DEPARTMENT

HOLD TIME STUDY PROTOCOL CUM REPORT FOR ORAL LIQUID

Annexure II

RESULTS OF FILTERED SOLUTION

BATCH NO. MFG. DATE

BATCH SIZE EXP. DATE

01 Days

02 Days

05 Days

07 Days
(Initial)
0 hours
S.No. Tests Limits

01 Description

02 pH Value

03 Wt.per ml

04 Assay

Additional Test

Microbial limit test

A. Total viable aerobic count

Aerobic NMT 102

bacteria cfu/g
05
NMT 101
Fungi
cfu/g

B. Pathogens

1. E. coli Absent

Compiled By________________ Reviewed By______________